Objectives: Elevated levels of high sensitivity C-reactive protein (hs-CRP)
Is associated with increased incidence of cardiovascular events. We aimed
to investigate whether iatrogenic disruption of plaques by percutaneous
coronary intervention (PCI) in patients with stable coronary artery disease
(CAD) would result in a meaningful rise in hs-CRP that could impact shortterm
outcome.
Methods: From September 2017 to May 2018, we measured hs-CRP in 60
patients divided into 3 groups; group I (20 patients with stable CAD undergoing
elective PCI), group II (20 patients with NSTE-ACS undergoing
PCI) and group 3 (20 patients with stable and unstable CAD undergoing
angiography without PCI). Samples for hs-CRP testing were withdrawn
before the procedure, 6 and 24 hours later.
Results: In group I, levels increased from 2.4 ± 0.6 at baseline to 8.2 ± 1.7
e2 Abstracts / Atherosclerosis Supplements 33 (2018) e1ee6
mg/L 24 hours later, P < 0.001). In group II, levels increased from 7.7 ± 2.9
at baseline to 12.2 ± 3.5 mg/L 24 hours later, P < 0.001). Group III showed
no significant change. The median percent change in group I was significantly
higher than both groups II and III (239.09% [117.86 - 566.67] versus
70.47% [- 19.09 - 212.24] and 10.98% [-27.59 - 272.73], P < 0.001). No significant
differences in baseline or 24 hours hs-CRP levels were found between
those who developed 30-day endpoints and those who did not.
Conclusion: Iatrogenic disruption of plaques by PCI in stable CAD resulted in a significant rise of hs-CRP. However, this does not impact short-term outcome.